Synergo for non-muscle-invasive bladder cancer - Medtech innovation briefing (MIB226)

Synergo uses radiofrequency-induced thermo-chemotherapeutic effect to give chemotherapy (mitomycin C). The briefing summarises the evidence (3 trials and 3 observational studies) and discusses key uncertainties, identified safety issues and cost.

Source:

National Institute for Health and Care Excellence